Neurocritical Care News

AUSTIN, Texas — Venous manometry and neuroimaging may provide additional value when diagnosing patients who do not meet criteria for idiopathic intracranial hypertension, according to a poster presented here.

The FDA has granted orphan drug designation to DTx-1252, an investigational small interfering RNA therapeutic to treat Charcot-Marie-Tooth disease type 1A.

MIAMI BEACH, Fla. — Treatment with ketamine may be an effective augmenter of risk mitigation for suicidality and effective modulator for suicide-related cognitive processing in adults, according to data presented here.

The FDA has granted 510(k) clearance to Neuronetics Inc. for its obsessive-compulsive disorder motor threshold cap technology for NeuroStar Advanced Therapy for Mental Health.

According to published results, adolescent football players may exhibit impairments in oculomotor functions and several blood biomarkers associated with subconcussive head impacts.

I want to reflect on a recent patient I admitted: a woman in her 40s who presented with an intractable headache.

Genentech announced positive results from its global phase 2 study evaluating the investigational oral Bruton’s tyrosine kinase inhibitor fenebrutinib in adults with relapsing forms of MS.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

BOSTON — Two studies presented at the American Academy of Neurology meeting showed treatment with Aptiom improved quality of life scores and reduced frequency in patients with focal seizures.